Literature DB >> 32167781

The contribution of chymase-dependent formation of ANG II to cardiac dysfunction in metabolic syndrome of young rats: roles of fructose and EETs.

Ghezal Froogh1, Sharath Kandhi1, Roopa Duvvi1, Yicong Le1, Zan Weng1, Norah Alruwaili1, Jonathan O Ashe1, Dong Sun1, An Huang1.   

Abstract

The roles of ACE-independent ANG II production via chymase and therapeutic potential of epoxyeicosatrienoic acids (EETs) in fructose-induced metabolic syndrome (MetS) in the adolescent population remain elusive. Thus we tested the hypothesis that a high-fructose diet (HFD) in young rats elicits chymase-dependent increases in ANG II production and oxidative stress, responses that are reversible by 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU), an inhibitor of soluble epoxide hydrolase (sEH) that metabolizes EETs. Three groups of weanling rats (21-day-old) were fed a normal diet, 60% HFD, and HFD with TPPU, respectively, for 30 days. HFD rats developed MetS, characterized by hyperglycemia, hyperinsulinemia, and hypertension and associated with decreases in cardiac output and stroke volume and loss of nitric oxide (NO) modulation of myocardial oxygen consumption; all impairments were normalized by TPPU that significantly elevated circulating 11,12-EET, a major cardiac EET isoform. In the presence of comparable cardiac angiotensin-converting enzyme (ACE) expression/activity among the three groups, HFD rats exhibited significantly greater chymase-dependent ANG II formation in hearts, as indicated by an augmented cardiac chymase content as a function of enhanced mast cell degranulation. The enhanced chymase-dependent ANG II production was paralleled with increases in ANG II type 1 receptor (AT1R) expression and NADPH oxidase (Nox)-induced superoxide, alterations that were significantly reversed by TPPU. Conversely, HFD-induced downregulation of cardiac ACE2, followed by a lower Ang-(1-7) level displayed in an TPPU-irreversible manner. In conclusion, HFD-driven adverse chymase/ANG II/Nox/superoxide signaling in young rats was prevented by inhibition of sEH via, at least in part, an EET-mediated stabilization of mast cells, highlighting chymase and sEH as therapeutic targets during treatment of MetS.NEW & NOTEWORTHY As the highest fructose consumers, the adolescent population is highly susceptible to the metabolic syndrome, where increases in mast cell chymase-dependent formation of ANG II, ensued by cardiometabolic dysfunction, are reversible in response to inhibition of soluble epoxide hydrolase (sEH). This study highlights chymase and sEH as therapeutic targets and unravels novel avenues for the development of optimal strategies for young patients with fructose-induced metabolic syndrome.

Entities:  

Keywords:  angiotensin II; chymase; high fructose; metabolic syndrome; soluble epoxide hydrolase

Mesh:

Substances:

Year:  2020        PMID: 32167781      PMCID: PMC7191492          DOI: 10.1152/ajpheart.00633.2019

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  47 in total

1.  Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis.

Authors:  Vaibhav B Patel; Sreedhar Bodiga; Ratnadeep Basu; Subhash K Das; Wang Wang; Zuocheng Wang; Jennifer Lo; Maria B Grant; JiuChang Zhong; Zamaneh Kassiri; Gavin Y Oudit
Journal:  Circ Res       Date:  2012-04-03       Impact factor: 17.367

Review 2.  Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease.

Authors:  Carlos M Ferrario; William B Strawn
Journal:  Am J Cardiol       Date:  2006-05-09       Impact factor: 2.778

3.  An essential role of NAD(P)H oxidase 2 in UVA-induced calcium oscillations in mast cells.

Authors:  Zhi Ying Li; Wen Yi Jiang; Zong Jie Cui
Journal:  Photochem Photobiol Sci       Date:  2015-02       Impact factor: 3.982

Review 4.  P-450 metabolites of arachidonic acid in the control of cardiovascular function.

Authors:  Richard J Roman
Journal:  Physiol Rev       Date:  2002-01       Impact factor: 37.312

5.  Inhibition of soluble epoxide hydrolase prevents diabetic retinopathy.

Authors:  Jiong Hu; Sarah Dziumbla; Jihong Lin; Sofia-Iris Bibli; Sven Zukunft; Julian de Mos; Khader Awwad; Timo Frömel; Andreas Jungmann; Kavi Devraj; Zhixing Cheng; Liya Wang; Sascha Fauser; Charles G Eberhart; Akrit Sodhi; Bruce D Hammock; Stefan Liebner; Oliver J Müller; Clemens Glaubitz; Hans-Peter Hammes; Rüdiger Popp; Ingrid Fleming
Journal:  Nature       Date:  2017-12-06       Impact factor: 49.962

6.  Primacy of cardiac chymase over angiotensin converting enzyme as an angiotensin-(1-12) metabolizing enzyme.

Authors:  Sarfaraz Ahmad; Jasmina Varagic; Jessica L VonCannon; Leanne Groban; James F Collawn; Louis J Dell'Italia; Carlos M Ferrario
Journal:  Biochem Biophys Res Commun       Date:  2016-07-25       Impact factor: 3.575

7.  Direct evidence for intrarenal chymase-dependent angiotensin II formation on the diabetic renal microvasculature.

Authors:  Sungmi Park; Benjamin J Bivona; Stephen M Ford; Sen Xu; Hiroyuki Kobori; Lawrence de Garavilla; Lisa M Harrison-Bernard
Journal:  Hypertension       Date:  2012-12-03       Impact factor: 10.190

8.  Major role for ACE-independent intrarenal ANG II formation in type II diabetes.

Authors:  Sungmi Park; Benjamin J Bivona; Hiroyuki Kobori; Dale M Seth; Mark C Chappell; Eric Lazartigues; Lisa M Harrison-Bernard
Journal:  Am J Physiol Renal Physiol       Date:  2009-10-21

Review 9.  Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases.

Authors:  John D Imig; Bruce D Hammock
Journal:  Nat Rev Drug Discov       Date:  2009-10       Impact factor: 84.694

10.  Chymase inhibition protects diabetic rats from renal lesions.

Authors:  Mei Zhang; Wen Huang; Jing Bai; Xiaodong Nie; Wen Wang
Journal:  Mol Med Rep       Date:  2016-05-10       Impact factor: 2.952

View more
  6 in total

Review 1.  Guidelines on models of diabetic heart disease.

Authors:  Lisa C Heather; Anne D Hafstad; Ganesh V Halade; Romain Harmancey; Kimberley M Mellor; Paras K Mishra; Erin E Mulvihill; Miranda Nabben; Michinari Nakamura; Oliver J Rider; Matthieu Ruiz; Adam R Wende; John R Ussher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-06-03       Impact factor: 5.125

2.  Nebivolol Prevents Up-Regulation of Nox2/NADPH Oxidase and Lipoperoxidation in the Early Stages of Ethanol-Induced Cardiac Toxicity.

Authors:  Gabriel T do Vale; Carla B P da Silva; Arthur H Sousa; Natália A Gonzaga; Juliana M Parente; Katiúscia M Araújo; Michele M Castro; Carlos R Tirapelli
Journal:  Cardiovasc Toxicol       Date:  2020-10-16       Impact factor: 3.231

3.  Effects of maternal fructose intake on the offspring's kidneys.

Authors:  Rogério Argeri; Erika Emy Nishi; Débora Conte Kimura Lichtenecker; Guiomar Nascimento Gomes
Journal:  Front Physiol       Date:  2022-09-06       Impact factor: 4.755

Review 4.  Molecular and cellular mechanisms in diabetic heart failure: Potential therapeutic targets.

Authors:  Misganaw Asmamaw Mengstie; Endeshaw Chekol Abebe; Awgichew Behaile Teklemariam; Anemut Tilahun Mulu; Assefa Agegnehu Teshome; Edgeit Abebe Zewde; Zelalem Tilahun Muche; Muluken Teshome Azezew
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-02       Impact factor: 6.055

Review 5.  Negative Effects of Chronic High Intake of Fructose on Lung Diseases.

Authors:  Adrián Hernández-Díazcouder; Javier González-Ramírez; Fausto Sanchez; José J Leija-Martínez; Gustavo Martínez-Coronilla; Luis M Amezcua-Guerra; Fausto Sánchez-Muñoz
Journal:  Nutrients       Date:  2022-10-01       Impact factor: 6.706

6.  Heart Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 Gene Expression Associated With Male Sex and Salt-Sensitive Hypertension in the Dahl Rat.

Authors:  Kirsti Ytrehus; Stian Ludvigsen; Costantino Mancusi; Eva Gerdts; Giovanni de Simone
Journal:  Front Physiol       Date:  2021-07-19       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.